Plain-English translation of NCT07134751 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This Swedish study is testing a new clinical guideline designed to help doctors make smarter decisions about which febrile babies aged 2 months or younger need immediate treatment for serious bacterial infections. Instead of treating all febrile infants the same way, the guideline combines what doctors observe about the baby's condition with specific blood test results to create a personalized risk assessment. This approach aims to reduce unnecessary procedures, hospital stays, and antibiotic exposure while still protecting babies from dangerous infections.
Currently, about 800,000 febrile babies per year in Europe and the US are hospitalized and given broad-spectrum antibiotics even though only 2–15% actually have serious infections. While doctors are trying to be cautious, this approach can cause harm: painful procedures, exposure to antibiotics that increases resistance and chronic disease risk, disrupted breastfeeding, family stress, and environmental waste. This study aims to develop guidelines that consider each baby's individual situation so fewer healthy babies undergo unnecessary interventions.
You likely qualify if…
You likely don't qualify if…
If your baby is enrolled, the study team will use the new clinical guideline to assess your baby's risk of serious infection based on physical examination and blood test results. Your baby may have blood tests performed, and the guideline will help doctors decide whether hospitalization and antibiotics are truly needed or if your baby can be safely monitored at home. The study will follow your baby's care and outcomes to see whether this personalized approach works as well as — or better than — the current standard practice.
AI-generated summary from trial data · Aug 23, 2026 · Not medical advice
Sweden